Quince Therapeutics publishes eDSP pharmacokinetic modeling study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. CL
5. LITE
6. LYB
7. TFII
8. NVT
9. SPY
10. AAPL

Go back to Quince Therapeutics publishes eDSP pharmacokinetic modeling study

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

September 25, 2025 4:05 PM EDT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, announced the publication of an advanced population pharmacokinetic (PK) modeling study of pediatric patients with Ataxia-Telangiectasia (A-T) and healthy adults treated with its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patients own red blood cells), in the scientific journal CPT: Pharmacometrics & Systems Pharmacology (PSP). The journal is an official open access journal of the American Society... More